Creating clinical target validation groups via quality assured transfer of robust clinical pharmacodynamic (PD) assays from the NCI: Clinical implementation of a PAR immunoassay in tumor biopsies.

Ralph E. Parchment,Robert J. Kinders,Jiuping Jay Ji,Apurva K. Srivastava,Katherine V. Ferry-Galow,Joseph E. Tomaszewski,James H. Doroshow

Creating clinical target validation groups via quality assured transfer of robust clinical pharmacodynamic (PD) assays from the NCI: Clinical implementation of a PAR immunoassay in tumor biopsies.

2017

Ralph E. Parchment
Robert J. Kinders
Jiuping Jay Ji
Apurva K. Srivastava
Katherine V. Ferry-Galow
Joseph E. Tomaszewski
James H. Doroshow

e22080 Background: Early phase clinical trials of investigational agents benefit from laboratory assays that quantify intended mechanism of action on molecular target (1° PD effects), desired chang...

Keywords:

Clinical trial
Pathology
Oncology
Mechanism of action
INVESTIGATIONAL AGENTS
Pharmacodynamics
Internal medicine
Immunoassay
Medicine
early phase
molecular targets

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations